Last reviewed · How we verify
Other Combination Anti-Cancer Therapies
Other Combination Anti-Cancer Therapies is a Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development for Various solid tumors and hematologic malignancies (specific combinations vary by pipeline program).
This is a category descriptor for multiple combination anti-cancer therapies rather than a single drug, typically involving synergistic use of two or more oncologic agents.
This is a category descriptor for multiple combination anti-cancer therapies rather than a single drug, typically involving synergistic use of two or more oncologic agents. Used for Various solid tumors and hematologic malignancies (specific combinations vary by pipeline program).
At a glance
| Generic name | Other Combination Anti-Cancer Therapies |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Combination anti-cancer therapies work by targeting multiple pathways or mechanisms simultaneously to improve efficacy and overcome resistance. Hoffmann-La Roche develops various combinations that may pair chemotherapy with targeted agents, immunotherapies with targeted drugs, or multiple immunotherapies to enhance anti-tumor activity.
Approved indications
- Various solid tumors and hematologic malignancies (specific combinations vary by pipeline program)
Common side effects
- Fatigue
- Nausea and vomiting
- Myelosuppression
- Immune-related adverse events
Key clinical trials
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors (PHASE1)
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (PHASE1)
- Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer (PHASE1, PHASE2)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas (PHASE1)
- A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other Combination Anti-Cancer Therapies CI brief — competitive landscape report
- Other Combination Anti-Cancer Therapies updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Other Combination Anti-Cancer Therapies
What is Other Combination Anti-Cancer Therapies?
How does Other Combination Anti-Cancer Therapies work?
What is Other Combination Anti-Cancer Therapies used for?
Who makes Other Combination Anti-Cancer Therapies?
What development phase is Other Combination Anti-Cancer Therapies in?
What are the side effects of Other Combination Anti-Cancer Therapies?
Related
- Manufacturer: Hoffmann-La Roche — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Various solid tumors and hematologic malignancies (specific combinations vary by pipeline program)
- Compare: Other Combination Anti-Cancer Therapies vs similar drugs
- Pricing: Other Combination Anti-Cancer Therapies cost, discount & access